Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

Inclusion Criteria

• •WBC \< 50,000/mm\^3 for patients with circulating tumor cells
• •No prior allergic reaction to compounds of similar chemical or biological composition to and presumably able to tolerated bortezomib, flavopiridol, allopurinol, sodium polystyrene sulfonate, or dexamethasone
• •No neuropathy \>= grade 2
• •No other condition that would preclude study participation
• •Not pregnant or nursing
• •Fertile patients must use effective contraception during and for 3 months after study participation
• •Prior autologous stem cell transplantation is allowed
• •No prior allogeneic stem cell transplantation
• •No other concurrent anticancer agents
• •No other concurrent investigational agents
• •Hemoglobin \>= 8 g/dL
• •Platelet count \>= 100,000/mm\^3
• •Absolute neutrophil count \>= 1,500/mm\^3
• •Bilirubin =\< 2 times upper limit of normal (ULN)
• •AST/ALT =\< 3 times ULN
• •Creatinine =\< 2 times ULN or Creatinine clearance \>= 50 mL/min